Nuclear Medicine
MIBG 131 WITHOUT CARRIER (R&D)
Name:
MIBG 131 without carrier (R&D)
Active Principle:
Iobenguan 131I
Therapeutic Action:
It is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years of age and older with iobenguane-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic antineoplastic therapy.
Nuclear Medicine
MIBG 131 WITHOUT CARRIER (R&D)
Name:
MIBG 131 without carrier (R&D)
Active Principle:
Iobenguan 131I
Therapeutic Action:
It is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years of age and older with iobenguane-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic antineoplastic therapy.
RELATED PRODUCTS
-
STANNOUS CHLORIDE
STANNOUS CHLORIDEIt is indicated for: - Performing scintigraphic studies of the blood pool of the heart and great vessels. - Circulatory and placental studies. - Evaluation of gastrointestinal bleeding (especially to locate... -
PARTITION FLASK
PARTITION FLASKVial containing a mixture of solvents to carry out a chromatographic separation ... -
FLPET (R+D)
FLPET (R+D)It is indicated for the detection and evaluation of cell proliferation in lung, breast, colorectal, melanoma, soft tissue sarcoma and primary or metastatic brain tumors. It allows to predict the aggressiveness... -
131I MIBG BACON (R&D)
131I MIBG BACON (R&D)It is indicated for the diagnosis and location of neuroendocrine tumors, pheochromocytoma, medullary thyroid cancer, primary neuroblastomas and their metastases, paragangliomas and thymomas...

